HealthStream (NASDAQ:HSTM) Director Sells $50,000.00 in Stock

HealthStream director Linda Rebrovick sold 2,000 shares on June 1 at an average $25.00, for $50,000, according to an SEC filing. After the sale, she owned 54,181 shares. The trade followed a Rule 10b5-1 plan. Separately, HealthStream reported May 4 quarterly EPS of $0.20 on $81.2M revenue and authorized a $10M buyback.

Original reporting
Published Jun 3, 2026, 7:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 7:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HealthStream (NASDAQ:HSTM) Director Sells $50,000.00 in Stock — source image
Decision brief

The 30-second read

$HSTMNeutralLow
01

Why it matters

Trading focus is on whether the insider sale changes sentiment despite being pre-planned; the fundamental backdrop includes a recent earnings beat and an active repurchase authorization.

02

Market read

For HSTM, this is a low-signal insider transaction with limited fundamental implications, but it can influence very short-term sentiment around the stock.

03

What to watch

The article also cites a recent earnings beat, dividend payment, and $10m repurchase authorization—these may offset any negative optics from the director sale.

Relevance 6/10Novelty 4/10Timing: pre-market/early-session context following the June 1 sale disclosure

Background

The piece centers on an SEC-disclosed director sale (2,000 shares) executed under a pre-arranged Rule 10b5-1 trading plan, plus a snapshot of recent earnings, buyback authorization, and dividend.

Company-level read

Ticker impact

$HSTMNeutralMedium confidence
Context

HealthStream director Linda Rebrovick sold 2,000 shares at ~$25 under a Rule 10b5-1 plan, disclosed via SEC filing.

Expected impact

Low-to-moderate near-term sentiment drag; likely limited fundamental impact unless follow-on selling accelerates.

Evidence & confidence

The article provides a specific Form 4-style sale size/price and confirms Rule 10b5-1 pre-arrangement, reducing the likelihood of a new negative fundamental catalyst.

Market effects

Limited read-through for healthcare LMS/workforce training peers; this is company-specific insider activity rather than sector regulation or contract news.

None material beyond US small/mid-cap sentiment.

None.

Counterpoint

Rule 10b5-1 sales can coincide with routine liquidity needs; the more actionable signal may be the company’s ongoing buyback authorization and recent earnings beat.

Key entities

  • HealthStream, Inc.

    NASDAQ-listed provider of healthcare workforce development and learning management solutions; subject of the director sale and recent corporate actions.

  • Linda Rebrovick

    HealthStream director who sold 2,000 shares at an average ~$25 under a Rule 10b5-1 plan.

Related articles

$NVSLowAI 8/10

Back to Back Heart Drug Failures at Novartis and Novo Nordisk Undercut Two Leading Theories of Cardiovascular Risk

Novartis' pelacarsen and Novo Nordisk's ziltivekimab failed in Phase 3 trials, testing different cardiovascular risk theories. Both drugs did not reduce cardiovascular events despite lowering targets. Novartis reported pelacarsen's Lp(a)HORIZON trial results, while Novo Nordisk halted ziltivekimab's HERMES and ATHENA trials. Analysts estimated pelacarsen's peak sales at $4B-$6B. Both companies have other trials ongoing.

$BAHighAI 9/10

US Navy awards Boeing first MQ-25A Stingray production contract

The US Navy awarded Boeing a $562M contract for the first three MQ-25A Stingray unmanned aerial refueling aircraft, with deliveries expected in 2029. The contract also funds components for three more aircraft. The MQ-25 program aims to produce 67 operational aircraft and nine test vehicles, with the Stingray designed to extend the service life of F/A-18 Super Hornet fighters by handling refueling missions.